<li>benazepril<p>morphine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension.</p></li><li>brimonidine<p>brimonidine increases effects of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.</p></li><li>celandine<p>celandine increases effects of morphine by unspecified interaction mechanism. Minor/Significance Unknown. Based on animal studies.</p></li><li>dextroamphetamine<p>dextroamphetamine increases effects of morphine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>eucalyptus<p>morphine and eucalyptus both increase  sedation. Minor/Significance Unknown.</p></li><li>lidocaine<p>lidocaine increases toxicity of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>naloxone<p>naloxone decreases effects of morphine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>rifabutin<p>rifabutin decreases levels of morphine by increasing metabolism. Minor/Significance Unknown.</p></li><li>rifampin<p>rifampin decreases levels of morphine by increasing metabolism. Minor/Significance Unknown.</p></li><li>sage<p>morphine and sage both increase  sedation. Minor/Significance Unknown.</p></li><li>ziconotide<p>ziconotide, morphine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Additive decreased GI motility. Additive analgesia. Ziconotide does NOT potentiate opioid induced respiratory depression.</p></li>